Drug Profile
Research programme: T-cell receptor therapeutics - Tmunity Therapeutics
Alternative Names: H3.3K27M TCR T cell therapyLatest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Tmunity Therapeutics
- Developer Tmunity Therapeutics; University of California at San Francisco; University of Pennsylvania
- Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Diffuse intrinsic pontine glioma; HIV infections
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for research development in Diffuse intrinsic pontine glioma(In children) in USA
- 22 Feb 2023 Tmunity Therapeutics has been acquired by Kite Pharma
- 28 Feb 2022 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)